Top-Rated StocksTop-RatedNASDAQ:BEAM Beam Therapeutics (BEAM) Stock Price, News & Analysis $15.27 -1.19 (-7.23%) Closing price 04:00 PM EasternExtended Trading$15.28 +0.01 (+0.03%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Beam Therapeutics Stock (NASDAQ:BEAM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Beam Therapeutics alerts:Sign Up Key Stats Today's Range$14.72▼$16.6750-Day Range$16.46▼$34.1652-Week Range$14.72▼$35.25Volume5.49 million shsAverage Volume1.84 million shsMarket Capitalization$1.52 billionP/E RatioN/ADividend YieldN/APrice Target$49.45Consensus RatingBuy Company OverviewBeam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Read More… Remove Ads Beam Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreBEAM MarketRank™: Beam Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 350th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingBeam Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageBeam Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Beam Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Beam Therapeutics are expected to grow in the coming year, from ($4.57) to ($4.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beam Therapeutics is -8.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beam Therapeutics is -8.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeam Therapeutics has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Beam Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.33% of the float of Beam Therapeutics has been sold short.Short Interest Ratio / Days to CoverBeam Therapeutics has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Beam Therapeutics has recently increased by 21.72%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldBeam Therapeutics does not currently pay a dividend.Dividend GrowthBeam Therapeutics does not have a long track record of dividend growth.Read more about Beam Therapeutics' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.33% of the float of Beam Therapeutics has been sold short.Short Interest Ratio / Days to CoverBeam Therapeutics has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Beam Therapeutics has recently increased by 21.72%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.43 News SentimentBeam Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Beam Therapeutics this week, compared to 7 articles on an average week.Search Interest18 people have searched for BEAM on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.MarketBeat Follows8 people have added Beam Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,605,698.00 in company stock.Percentage Held by InsidersOnly 4.20% of the stock of Beam Therapeutics is held by insiders.Percentage Held by Institutions99.68% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Beam Therapeutics' insider trading history. Receive BEAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BEAM Stock News HeadlinesChristine Bellon Sells 5,674 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) StockApril 4 at 5:52 AM | insidertrades.comIs Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy?April 3 at 12:18 AM | finance.yahoo.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 4, 2025 | Porter & Company (Ad)Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy?April 2 at 11:38 AM | msn.comThe Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR TherapeuticsMarch 31, 2025 | finance.yahoo.comBeam Therapeutics (NASDAQ:BEAM) Upgraded to "Buy" at Bank of AmericaMarch 29, 2025 | americanbankingnews.comBeam Therapeutics upgraded to Buy at BofA after BEAM-302 dataMarch 28, 2025 | markets.businessinsider.comBeam Therapeutics upgraded to Buy from Neutral at BofAMarch 28, 2025 | markets.businessinsider.comSee More Headlines BEAM Stock Analysis - Frequently Asked Questions How have BEAM shares performed this year? Beam Therapeutics' stock was trading at $24.80 at the beginning of 2025. Since then, BEAM stock has decreased by 38.9% and is now trading at $15.1650. View the best growth stocks for 2025 here. How were Beam Therapeutics' earnings last quarter? Beam Therapeutics Inc. (NASDAQ:BEAM) issued its quarterly earnings results on Tuesday, February, 25th. The company reported ($1.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.25) by $0.16. The firm's revenue for the quarter was down 90.5% compared to the same quarter last year. Does Beam Therapeutics have any subsidiaries? Beam Therapeutics subsidiaries include these companies: Blink Therapeutics Inc.. When did Beam Therapeutics IPO? Beam Therapeutics (BEAM) raised $101 million in an initial public offering (IPO) on Thursday, February 6th 2020. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. How do I buy shares of Beam Therapeutics? Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Beam Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Beam Therapeutics investors own include Chevron (CVX), Bristol-Myers Squibb (BMY), Comcast (CMCSA), Charles Schwab (SCHW), Edwards Lifesciences (EW), McKesson (MCK) and Yum! Brands (YUM). Company Calendar Last Earnings2/25/2025Today4/04/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BEAM CIK1745999 Webwww.beamtx.com Phone857-327-8775FaxN/AEmployees510Year Founded2017Price Target and Rating Average Stock Price Target$49.45 High Stock Price Target$80.00 Low Stock Price Target$26.00 Potential Upside/Downside+200.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($4.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-132,530,000.00 Net Margins-41.07% Pretax Margin-40.67% Return on Equity-16.22% Return on Assets-10.94% Debt Debt-to-Equity RatioN/A Current Ratio5.69 Quick Ratio5.69 Sales & Book Value Annual Sales$63.52 million Price / Sales25.86 Cash FlowN/A Price / Cash FlowN/A Book Value$12.04 per share Price / Book1.37Miscellaneous Outstanding Shares99,785,000Free Float79,328,000Market Cap$1.64 billion OptionableOptionable Beta2.02 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:BEAM) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredEU’s Action Takes Aim At US RetireesTrump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.